Navigation Links
Cellceutix CEO, Leo Ehrlich, Conducts Interview with "Biotech Stock Trader"; Dr. Paul Ginsberg, (Renowned Patent Attorney) Joins Cellceutix Advisory Board
Date:4/18/2011

BEVERLY, Mass., April 18, 2011 /PRNewswire/ -- Cellceutix Corporation (OTCQB: CTIX, "the Company"), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions including drug-resistant cancers, is pleased to announce that its CEO Leo Ehrlich has conducted an interview with Biotech Stock Trader, a news and information portal for investors in pharmaceutical and biotechnology firms.  The interview provides additional insight into Cellceutix, the future path of the Company, and its business model. The company's potential and developments are discussed as well as the Cellceutix pipeline, upcoming clinical trials, and the Company's potential revolutionary cancer medication breakthrough with Kevetrin™ to reactivate p53, the "Guardian Angel of the Human Genome."

The interview is available for viewing on the Cellceutix website at http://www.cellceutix.com/news/BiotechStockTrader.html and at http://biotechstocktrader.com/cellceutix-otcqb-ctix-management-outlines-enormous-potential-in-exclusive-interview-200/.

Cellceutix also is pleased to announce that they have added renowned patent attorney, Dr. Paul Ginsberg, to their Advisory Board.

Cellceutix CEO Leo Ehrlich commented, "We are excited that Dr. Ginsberg wanted to expand his relationship with Cellceutix. Dr. Ginsberg has already been of great help in the patent process of Kevetrin™ and we look forward to his knowledge and experience as we finalize the patent application for our autism drug.  Dr. Ginsberg, with his in depth understanding of pharmaceutical chemistry, is a perfect fit to join our other amazing scientific advisors who have been of such enormous help to our early and extraordinary scientific successes. "

Commenting on joining the Cellceutix Advisory Board, Dr. Ginsburg stated, "I have been working closely with Cellceutix and Dr. Menon for some time now and based on my past experience in the field, I see great potential in the Company.  I am both pleased and excited to join the exceptional Cellceutix team and look forward to what the future may hold with not only Kevetrin™, but KM-391 for autism and other drugs in the pipeline which I have gotten to know quite well."

About Dr. Ginsberg

Dr. Ginsburg received his Ph.D. in Chemistry from the City University of New York and his law degree from Columbia University where he was a Harlan Fiske Stone Scholar.  He was elected to Phi Beta Kappa at the City College of New York and to the scientific research honor society Sigma Xi at CUNY. 

Dr. Ginsburg has spent most of his career as corporate counsel representing large and small pharmaceutical, biotechnology, chemical and consumer products companies.  His last position was at Pfizer Inc., where he served as Head of the New York Patent Department which dealt with several blockbuster products, including Viagra and Chantix.  He represented Pfizer on the intellectual property committees of the National Association of Manufacturers, the Chemical Manufacturers Association and the Biotechnology Industry Organization. Dr. Ginsburg has lectured widely on pharmaceutical and biotechnology patent prosecution and licensing at the Practicing Law Institute and Columbia Law School . Prior to his twenty year career at Pfizer, Dr. Ginsburg was a senior attorney at Schering-Plough. He was subsequently recruited by Merck and then by the highly respected IP law firm, Fish & Neave.

Dr. Ginsburg is perhaps most well-known as the author of the patent covering Schering-Plough's hugely successful product Claritin. He also authored important patents covering Schering-Plough's highly successful alpha-interferon product.

Dr. Ginsburg has authored the patent application for Cellceutix anticancer product Kevetrin™, which has been filed in the United States and other countries and has advised Cellceutix on patent and licensing matters during the past few years.

About Cellceutix

Cellceutix Corporation is a preclinical cancer, anti-inflammatory and autism drug developer. Cellceutix owns the rights to eight drug compounds, including Kevetrin, which it is developing as a treatment for certain cancers, KM-133, for the treatment of psoriasis, and KM-391, for the treatment of autism. More information is available on the Cellceutix web site at www.cellceutix.com.

This Press Release contains forward-looking statements that are based on our current expectations, beliefs and assumptions about the industry and markets in which Cellceutix Corporation operates. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause Cellceutix's actual results to be materially different from any future results expressed or implied by these statements. Actual results may differ materially from what is expressed in these statements, and no assurance can be given that Cellceutix can successfully implement its core business strategy and improve future earnings.

The factors that may cause Cellceutix's actual results to differ from its forward-looking statements include: Cellceutix's current critical need for additional cash to sustain existing operations and meet ongoing existing obligations and capital requirements; Cellceutix's ability to implement its new product development and commercialization, enter into clinical trials, expand the intellectual property portfolio, and receive regulatory approvals in a timely and cost-effective manner. All forward-looking statements are also expressly qualified in their entirety by the cautionary statements included in Cellceutix's SEC filings, including its quarterly reports on Form 10-Q and its annual report on Form 10-K.

Kevetrin, KM133, and KM-391 have not been studied in humans at this time. The Company's positive results in animal studies do not necessarily guarantee success in humans, though they may form the basis for beginning Phase 1 trials.


'/>"/>
SOURCE Cellceutix Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cellceutix Poster Presentation on its p53 Cancer Breakthrough Attracts Wide Interest at 102nd AACR Meeting
2. Cellceutix Reports Production of Its Anti-Cancer Drug Kevetrin™ Has Begun
3. Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company
4. Cellceutix Discovers Drug Activates Guardian Angel p53 in Fight Against Leukemia
5. Cellceutix Cancer Drug Kevetrin™ Shows No Genotoxicity in Study
6. Sonic Innovations Conducts National Training Events for Government Clinicians
7. Impliant Conducts the First Two Implantations of Its New TOPS VersaLink Spinal System
8. Tibotec Conducts Two Pivotal Phase III Clinical Trials Studying TMC278 in Treatment-Naive Adults with HIV
9. Maine Natural Health Company Conducts Dental Clinical Trial
10. OXIS International Executives Interviewed on StockGoodies.com Radio
11. Cardiogenesis Executive Chairman Paul J. McCormick Updates Commercial and Regulatory Progress in Interview With Wall Street Reporter, Available Online
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... , July 10, 2017 The Institute for ... methods, is the recipient of a VITROCELL® inhalation exposure ... International Science Consortium. The device, which is designed to ... expose human lung cells to airborne test materials in ... use the VITROCELL® system for testing combustible tobacco products, ...
(Date:7/10/2017)... , July 10, 2017  The tenth annual ... Boston, MA at the Sheraton Boston Hotel, ... unparalleled access to global decision makers and innovative biotech ... life science leaders during two impactful days. BioPharm America ... delegates with additional networking opportunities with 4,500+ life science ...
(Date:7/6/2017)... CINCINNATI , July 6, 2017 ThriveRx, the nutrition division ... and their families to thrive on nutrition support. To celebrate ... The new site has a fresh new look with improved organization to ... ... ...
Breaking Medicine Technology:
(Date:7/22/2017)... ... July 22, 2017 , ... More than ... of patients not requiring pain medication after three months post-operatively. However, researchers presenting ... Meeting today in Toronto, Ontario, Canada found that those patients who were filling ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Ellis Agency, an eastern Georgie provider ... in a community wide charity event with the goal of bringing in support for ... woman who lives with epilepsy, recently launched a charity campaign of her own by ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... ... Philadelphia and Theater of Witness , was awarded a $300,000 grant ... humanities program which fosters empathy, comfort with ambiguity and the recognition of one’s ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... received a $5,000 grant from the C. R. Bard Foundation, Inc. ... at Somerset Hills , a service available through the nonprofit home care agency. ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... ... follow-up at 10 years, researchers from the Multicenter Orthopaedics Outcome Network (MOON) demonstrated ... life a decade after surgery, though activity levels decline over time. The study, ...
Breaking Medicine News(10 mins):